Ticagrelor recommended over clopidogrel in STEMI patients

References

• Silvain J, Collet J-P, Nagaswami C, et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol. 2011 Mar 22;57(12):1359–1367.
   PubMed Web of Science ®Google Scholar
• Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122(6):776–781.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Theodoropoulos KC, Stavrou EF, et al. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovasc Drugs Ther. 2012 Oct;26(5):393–400.
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010 Oct 26;56(18):1456–1462.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Kontoprias K, Gkizas V, et al. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, pharmacodynamic comparison. Platelets. 2016;27:420–426.
   PubMed Web of Science ®Google Scholar
• Steg PG, James S, Harrington RA, et al.; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122:2131–2141.
   PubMed Web of Science ®Google Scholar
• Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct; 33(20):2569–2619.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2013;61:e78–e140.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Deftereos S, et al.; GRAPE Investigators. Contraindications/special warnings and precautions for use of contemporary oral antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Circ J 2014;78(1):180–187.
   PubMed Web of Science ®Google Scholar
• Velders MA, Abtan J, Angiolillo DJ, et al. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 2016;Apr15102(8):617–625. Epub 2016 Feb 4. PLATO Investigators.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012 Dec;5(6):797–804.
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014 Dec 31;8(1):e001593. doi:10.1161/CIRCINTERVENTIONS.114.001593.
   PubMed Web of Science ®Google Scholar
• Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016 Jan 14;37(3):245–252.
   PubMed Web of Science ®Google Scholar
• Zeymer U, Arntz HR, Mark B, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol. 2012;101:305–312.
   PubMed Web of Science ®Google Scholar
• Montalescot G, van ‘t Hof AW, Lapostolle F, et al.; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016–1027.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? Eur Heart J. 2016 Apr 21;37(16):1284–1295.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Moulias A, Kanakakis I, et al. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: ready for prime time? Int J Cardiol. 2015 Sep;1(194):41–43.
   Web of Science ®Google Scholar
• Parodi G, Xanthopoulou I, Bellandi B, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;10(65):511–512.
   Web of Science ®Google Scholar
• Alexopoulos D, Barampoutis N, Gkizas V, et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clin Pharmacokinet. 2016 Mar;55(3):359–367.
   PubMed Web of Science ®Google Scholar
• Moudgil R, Al-Turbak H, Osborne C, et al.; CAPITAL Investigators. Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia. Can J Cardiol. 2014 Nov; 30(11):1396–1399.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. CHAMPION PHOENIX Investigators. N Engl J Med. 2013;368(14):1303–1313.
   PubMed Web of Science ®Google Scholar